Neuromyelitis Optica

• Aquaporin-4 Antibody Formation and Complement Activation: In seropositive NMO (AQP4-IgG positive, ~80% of cases), autoreactive B cells produce IgG antibodies against AQP4, a water channel expressed at high density on astrocytic end-feet that form the glia limitans at the blood-brain barrier and perivascular spaces. These AQP4-IgG antibodies bind to conformational epitopes on the extracellular domain of AQP4, particularly in clustered arrays at astrocytic membranes. Once bound, these antibodies activate the classical complement cascade via IgG Fc domain engagement with C1q, leading to formation of the membrane attack complex (MAC, C5b-9). This massive complement-mediated lysis of AQP4-expressing astrocytes creates a cytotoxic lesion characterized by astrocytic death, blood-brain barrier disruption, vasogenic edema, and secondary oligodendrocyte apoptosis. The resulting lesions are typically large and longitudinally extensive (LETM: >3 contiguous spinal cord segments), distinguishing NMO from MS. This antibody-driven mechanism explains why plasma exchange (removing circulating antibodies) and B-cell targeting therapies are effective, and why high-dose corticosteroids suppress the immune response early in attacks.

• Cellular Immunity and T-Cell Involvement: Beyond antibody-mediated complement activation, NMO involves dysregulated cellular immunity with elevated Th17 and Th1 CD4+ T cells producing IL-17 and IFN-γ. These pro-inflammatory cytokines breach the blood-brain barrier, recruit neutrophils and macrophages, and amplify local inflammation. Th17 cells and their IL-17 production are particularly important in NMO pathogenesis, as IL-17 reduces tight junction protein expression (claudins, occludin, ZO-1), directly compromising blood-brain barrier integrity independent of AQP4 antibodies. Neutrophil infiltration contributes to tissue damage through degranulation and production of reactive oxygen species. Additionally, pathogenic CD8+ T cells may directly target astrocytes or oligodendrocytes, contributing to demyelination. This cellular immune component explains why longer-term immunosuppression (beyond acute corticosteroids) prevents relapse and why T-cell targeting agents like fingolimod show efficacy.

• Aquaporin-4 Seronegative Pathophysiology (AQP4-IgG Negative, ~20% of Cases): In seronegative NMO, disease mechanisms remain incompletely understood but likely involve antibodies against other astrocytic or myelin antigens. Recent evidence suggests some seronegative cases may involve antibodies against myelin oligodendrocyte glycoprotein (MOG), which shares immunological cross-reactivity with astrocytic proteins or acts through similar demyelinating mechanisms. MOG-IgG positive cases represent a distinct entity with somewhat different clinical features but similar treatment principles. Seronegative cases lacking both AQP4 and MOG antibodies may involve T-cell dominant mechanisms or antibodies against unidentified antigens. Importantly, seronegative NMO clinically resembles seropositive disease with similar lesion patterns and responsiveness to immunosuppression, suggesting a shared final common pathway of astrocytic and oligodendrocyte damage even if the initial trigger differs.

• Blood-Brain Barrier Disruption and Vasogenic Edema: AQP4 on astrocytic end-feet regulates water homeostasis and maintains osmotic gradients critical for BBB function. AQP4 antibody-mediated astrocytic loss removes this regulatory mechanism, leading to profound vasogenic edema that exceeds that seen in MS lesions. This edema contributes to cord swelling, cavitation (visible on MRI), and acute cord dysfunction. The loss of the astrocytic barrier also permits increased leakage of blood products, immune cells, and circulating factors into the CNS, amplifying the inflammatory cascade. This mechanism explains the frequent presence of hemorrhage within NMO lesions (hemosiderin staining, microhemorrhages) and the need for aggressive anti-inflammatory treatment to limit edema and secondary cord infarction.

• Oligodendrocyte Loss and Demyelination: While astrocytes are the primary target, oligodendrocytes (which produce myelin) are secondarily damaged through multiple mechanisms: direct complement-mediated lysis, excitotoxicity from glutamate released by dying astrocytes, destruction by infiltrating macrophages and neutrophils, and lack of astrocytic support factors. This secondary oligodendrocyte depletion results in demyelination that is typically more severe and extensive than in MS. The combination of astrocytic loss and oligodendrocyte apoptosis creates lesions with minimal remyelination capacity, explaining the greater irreversibility of deficits in NMO versus MS. However, some remyelination can occur if oligodendrocyte precursor cells are preserved or if chronic immunosuppression is established early.

• Tissue-Resident Memory T Cells and Relapse Mechanism: NMO typically follows a relapsing-remitting course in 90% of patients, with relapses separated by months to years. Tissue-resident memory T cells (TRM) that persist in CNS lesions contribute to relapses by rapidly re-engaging local antigens and recruiting fresh waves of B cells and antibody-producing plasma cells. These long-lived plasma cells resident in the bone marrow persist despite B-cell depleting therapies, explaining why continued immunosuppression is necessary even during remission. The meningeal lymphoid tissues also harbor AQP4-specific B cells, creating a protected sanctuary from some immunosuppressive agents, which partially explains treatment failures and the necessity of adequate CNS penetration for maintenance therapies.

• Aquaporin-4 (AQP4) Autoimmunity (Primary Cause): The presence of AQP4-IgG seropositivity is the defining feature of neuromyelitis optica spectrum disorder (NMOSD) in seropositive cases. The development of AQP4 antibodies likely results from a combination of genetic susceptibility and environmental triggers that break B-cell tolerance to this self-antigen. AQP4 is normally expressed at high levels on astrocytic end-feet, and for unclear reasons, some individuals develop pathogenic IgG responses against this protein. The mechanism initiating AQP4 autoimmunity may involve molecular mimicry (cross-reactivity between AQP4 and epitopes on pathogenic microorganisms), bystander activation during CNS infection, or defective regulatory T-cell (Treg) function. Once initiated, AQP4-specific B cells differentiate into antibody-secreting plasma cells and memory B cells, establishing a self-perpetuating autoimmune response.

• HLA Genetic Susceptibility: Strong HLA associations exist for NMO, with HLA-DPA1 and HLA-DPB1 showing the strongest associations across multiple ethnic groups, and **HLA-B*52:01** strongly associated in East Asian populations. These MHC class II molecules present AQP4-derived peptides to CD4+ T helper cells, facilitating Th17 differentiation and B-cell activation. The ethnic variation in HLA associations partly explains the higher prevalence of NMO in non-Caucasian populations. HLA-A*02:01 shows a protective association, suggesting that certain HLA-peptide combinations preferentially select for autoreactive T cells. Genome-wide association studies (GWAS) have also identified non-HLA susceptibility loci including those in IL6R, IL7R, and FAM213A, suggesting involvement of IL-6/IL-7 signaling and other immune pathways in disease susceptibility.

• Female Sex and Sex Hormones: Women comprise ~80% of NMO cases, with disease onset typically during reproductive years (20–50 years). This striking female predominance implicates estrogen signaling in promoting AQP4-specific B cell and Th17 cell responses. Estrogen enhances B-cell survival and antibody production through estrogen receptor signaling on B cells and dendritic cells. Estrogen also promotes IL-17 production from Th17 cells. Pregnancy can trigger disease exacerbation in the postpartum period, suggesting that hormonal shifts influence disease activity. Conversely, some women experience clinical improvement with oral contraceptive use, though this is not a consistent finding. The role of sex hormones explains why immunosuppressive strategies targeting B cells and Th17 cells are particularly effective in this predominantly female population.

• Infections as Immunological Triggers: Viral infections, particularly respiratory and gastrointestinal infections caused by enteroviruses, influenza, and other respiratory viruses, have been temporally associated with NMO attacks. Molecular mimicry between viral antigens and AQP4 peptides may break tolerance in genetically susceptible individuals. Bacterial infections (including Mycoplasma pneumoniae) have also been reported preceding NMO onset. In some cases, infections may provide the bystander activation signal that recruits autoreactive T cells to the CNS. However, infections are not uniformly identified in all NMO patients, suggesting that other triggers (autoimmune conditions, malignancy, radiation) can initiate disease in the absence of a clear infectious prodrome.

• Systemic Autoimmune Diseases (Secondary NMO): NMO can occur in association with systemic lupus erythematosus (SLE), Sjögren's syndrome, myasthenia gravis, thyroid disease, and other autoimmune disorders, though less commonly than with MS. This co-occurrence in 10–15% of NMO patients suggests shared pathogenic mechanisms of autoimmunity. Some patients with NMO have concurrent anti-nuclear antibodies (ANAs) or other autoantibodies without meeting criteria for a specific connective tissue disease, representing an overlap syndrome. The presence of systemic autoimmunity may reflect broader breakdown of immune tolerance in these individuals and may require treatment of the underlying autoimmune condition in addition to NMO-specific therapy.

• Malignancy (Paraneoplastic NMO): Rarely, NMO can occur as a paraneoplastic syndrome associated with lung cancer, breast cancer, ovarian cancer, and lymphoma. These malignancy-associated cases typically present with AQP4 seropositivity and may respond to cancer treatment. The mechanism likely involves molecular mimicry between tumor antigens and AQP4 epitopes or immune dysregulation from the malignancy itself. Screening for occult malignancy is reasonable in patients with NMO, particularly older adults with limited prior medical history.

• Prior Vaccination and Environmental Exposures: Case reports describe temporal associations between NMO onset and vaccinations (particularly hepatitis B, tetanus, and COVID-19 vaccines), though causality remains unproven and the overall risk is extremely low. Environmental factors such as latitude (lower risk at higher latitudes, inversely correlated with multiple sclerosis), ultraviolet light exposure, and vitamin D insufficiency show associations in some studies. Smoking has not shown consistent association with NMO unlike MS, suggesting different environmental risk profiles.

• Seronegative NMO and MOG Antibodies: Approximately 20% of NMO cases are seronegative for AQP4-IgG but may be positive for myelin oligodendrocyte glycoprotein (MOG)-IgG (~40% of seronegative cases). MOG is a myelin surface antigen expressed on oligodendrocytes and myelin, and MOG-IgG seropositive disease represents a related but distinct condition with slightly different clinical features. MOG-IgG seropositive patients tend to have more simultaneous bilateral optic neuritis, shorter spinal lesions, and better response to some immunosuppressive agents. The etiology of MOG antibody development is similarly thought to involve genetic predisposition and environmental triggers similar to AQP4 disease.

• Optic Neuritis (Vision Loss): Optic neuritis is the initial presentation in ~40% of patients and occurs at some point in >99% of NMO patients over their disease course. Patients typically experience acute unilateral vision loss (occasionally bilateral, particularly simultaneous bilateral optic neuritis which is rare in MS but relatively common in NMO) developing over hours to days. Pain on eye movement (retroorbital pain with extraocular movement) is less common in NMO optic neuritis than in MS optic neuritis. Visual acuity may range from mild blurring to complete blindness (hand motion or light perception only). Relative afferent pupillary defect (RAPD) is present in unilateral cases, while bilateral simultaneous optic neuritis may not produce an obvious RAPD. Visual fields demonstrate central scotomas (central vision loss) or altitudinal defects depending on the location of demyelination within the optic nerve. Color vision is reduced (tested with red desaturation or Ishihara plates), reflecting optic nerve demyelination. Fundoscopic examination during acute phase may show optic disc edema or appear normal (retrobulbar neuritis). Importantly, optic neuritis in NMO causes more severe vision loss and worse visual recovery compared to MS, with ~55% of patients experiencing permanent visual impairment in at least one eye after first event. Recurrent optic neuritis is common in NMO, with ~60% experiencing multiple episodes, distinguishing it from MS where optic neuritis is often a one-time event.

• Acute Myelitis (Spinal Cord Inflammation): Myelitis is the presenting manifestation in ~40% of NMO patients and occurs in virtually all patients over the disease course. Patients develop subacute paraparesis or tetraparesis (depending on lesion level) over hours to days, sometimes preceded by acute onset back or neck pain at the level of inflammation. Lower extremity weakness predominates when thoracic cord is affected, while cervical cord involvement produces weakness of all four limbs. Associated symptoms include sensory level changes (numbness from a defined dermatomal level downward), urinary retention or incontinence (from sacral cord involvement), constipation (autonomic dysfunction), and loss of temperature sensation with relatively preserved vibration sense (crossing spinothalamic tract involvement with dorsal column sparing is characteristic). The severity of acute myelitis in NMO exceeds that in MS, with patients often progressing to paraplegia or tetraplegia within days of symptom onset; approximately 50% of patients with inaugural myelitis are wheelchair-dependent at peak disability. Pain is a prominent feature in NMO myelitis, including lhermitte sign (electric shock sensation with neck flexion) caused by demyelination of cervical dorsal columns, or bilateral leg pain and truncal pain from spinothalamic tract involvement. Neuropathic pain from spinal demyelination persists as a chronic symptom in many patients even after inflammation resolves.

• Simultaneous Optic Neuritis and Myelitis (ADEM-like presentation): Approximately 15% of patients present with **simult

Step 1 — Imaging the affected neuraxis

• MRI spine with gadolinium: the screening study in any suspected myelitis. The signature lesion is longitudinally extensive transverse myelitis (LETM) — a T2-hyperintense lesion spanning ≥3 contiguous vertebral segments, centered on the central gray matter, often with cord swelling, T1 hypointensity, and bright spotty lesions. MS cord plaques, by contrast, are short (<2 segments) and peripheral/dorsolateral.
• MRI orbits/brain: NMOSD optic neuritis characteristically involves the posterior optic nerve, more than half its length, or the chiasm (producing bitemporal-type field loss). Brain MRI is often normal early or shows lesions in AQP4-rich regions — periependymal around the third/fourth ventricles, area postrema (dorsal medulla), hypothalamus, and corpus callosum — not the ovoid periventricular Dawson's fingers of MS.

Step 2 — Confirmatory serology (the gold standard)

• Serum AQP4-IgG by cell-based assay (CBA): the single most specific test, approaching near-total specificity. Order serum, not CSF — sensitivity is higher in serum. Live or fixed CBA outperforms ELISA and indirect immunofluorescence; a negative ELISA in a convincing clinical case should be repeated by CBA before calling the patient seronegative. Draw before plasma exchange and ideally before high-dose steroids.
• MOG-IgG by CBA: send if AQP4-IgG is negative, since MOG antibody-associated disease is a separate entity with different prognosis.

Step 3 — Supporting studies

• CSF: may show marked pleocytosis, sometimes >50 cells/µL with neutrophils or eosinophils — a pattern essentially never seen in MS. Oligoclonal bands are absent in the large majority of NMOSD (present in >85% of MS).
• Serologic screen: ANA, SSA/SSB, TSH, given the lupus/Sjögren/thyroid overlap.

Acute attack (treat urgently — deficits become fixed)

• High-dose IV corticosteroids: methylprednisolone 1 g IV daily for 5 days is the standard first-line attack therapy, suppressing complement-driven inflammation and vasogenic edema. Follow with an oral taper rather than abrupt discontinuation, as early rebound attacks occur.
• Therapeutic plasma exchange (PLEX): escalate early — within days, not weeks — for steroid-refractory or severe attacks (dense paraplegia, near-blindness). PLEX physically removes circulating AQP4-IgG and complement components; the American Society for Apheresis (ASFA) assigns apheresis a supported indication in NMOSD attacks. Many centers now start PLEX concurrently with steroids in severe presentations. IVIG is a second-line alternative when PLEX is unavailable.

Maintenance immunotherapy (start after the first attack — do not wait for a relapse)

• Complement C5 inhibitors: eculizumab, ravulizumab — FDA-approved for AQP4-IgG seropositive NMOSD; block MAC formation, the terminal step of the pathway described above.
• Anti-CD19 B-cell depletion: inebilizumab — FDA-approved for seropositive disease; depletes plasmablasts as well as B cells.
• IL-6 receptor blockade: satralizumab — FDA-approved for seropositive disease; IL-6 drives plasmablast survival and Th17 responses.
• Off-label agents: anti-CD20 rituximab, azathioprine (check TPMT/NUDT15), mycophenolate mofetil, tocilizumab — widely used, particularly in seronegative patients, for whom the three FDA-approved biologics are not labeled.

Contraindicated / harmful

• MS disease-modifying therapies: interferon-beta, natalizumab, alemtuzumab, and sphingosine-1-phosphate modulators (fingolimod) can precipitate severe NMOSD relapses and are avoided — the central reason misdiagnosis as MS is dangerous.
• Mycophenolate is teratogenic and contraindicated in pregnancy; azathioprine and rituximab are the more commonly used options in women planning conception.
• Meningococcal vaccination is mandatory before C5 inhibitors (FDA boxed warning for life-threatening Neisseria meningitidis infection).

Disease-related

• Permanent blindness: complement-mediated destruction of the optic nerve with poor remyelination; signaled by failure of visual acuity to recover after an attack and progressive retinal nerve fiber layer thinning on OCT. Bilateral or chiasmal attacks are the highest-risk pattern.
• Neurogenic bladder and recurrent urosepsis: sacral cord involvement causes detrusor–sphincter dyssynergia and incomplete emptying; signaled by elevated post-void residual, recurrent UTI, or unexplained fever with worsening spasticity (a pseudo-relapse).
• Cervical myelitis with neurogenic respiratory failure — EMERGENCY: lesions extending above C5 impair phrenic output. Signaled by falling vital capacity/negative inspiratory force and paradoxical abdominal breathing; hypercapnia is a late finding. Requires ICU monitoring.
• Area postrema syndrome: intractable hiccups, nausea, and vomiting from the dorsal medullary chemoreceptor trigger zone; leads to dehydration, aspiration, and weight loss and is frequently misattributed to a GI cause.
• Neuropathic pain, painful tonic spasms, and spasticity; also depression and reduced quality of life.

Treatment-related

• Meningococcal sepsis with C5 inhibitors — EMERGENCY: terminal complement blockade cripples MAC-dependent killing of Neisseria. Any fever in a patient on eculizumab or ravulizumab is a medical emergency requiring immediate cultures and empiric antibiotics despite prior vaccination.
• Hypogammaglobulinemia and infection with B-cell depletion: rituximab or inebilizumab; monitor IgG levels. Screen for hepatitis B before anti-CD20 therapy (reactivation risk); rare progressive multifocal leukoencephalopathy.
• IL-6 blockade (satralizumab, tocilizumab): blunts fever and CRP so infection presents silently; transaminitis, neutropenia, and rare GI perforation.
• Azathioprine: myelosuppression, especially with TPMT/NUDT15 deficiency; long-term malignancy risk.
• Corticosteroids: hyperglycemia, osteoporosis, avascular necrosis, psychosis.
• PLEX: central line infection/pneumothorax, citrate-induced hypocalcemia, hypotension, coagulopathy.

• LETM is the single most tested image: a T2 cord lesion spanning ≥3 contiguous vertebral segments with central cord involvement. Short, peripheral, dorsolateral plaques point to MS instead.
• Best next step after LETM or severe/bilateral optic neuritis: send serum AQP4-IgG by cell-based assay — not CSF, not ELISA alone. It is the confirmatory test and drives eligibility for all three FDA-approved biologics.
• Intractable hiccups, nausea, and vomiting in a young woman with prior optic neuritis = area postrema syndrome. Examiners love this stem because it masquerades as gastroenteritis; the lesion is in the dorsal medulla.
• CSF discriminates NMOSD from MS: marked pleocytosis with neutrophils or eosinophils and absent oligoclonal bands favor NMOSD; OCBs are present in the large majority of MS.
• The one association to know: NMOSD clusters with other autoimmune disease — SLE, Sjögren's, myasthenia gravis, autoimmune thyroid disease. A positive SSA/SSB does not exclude NMOSD; it supports it.
• The classic distractor is treating it as MS. Interferon-beta, natalizumab, alemtuzumab, and fingolimod can trigger devastating relapses. If a stem gives a patient who worsened dramatically after starting an MS drug, the diagnosis is NMOSD.
• Acute attack algorithm: IV methylprednisolone first; escalate early to plasma exchange if there is no rapid improvement — the antibody is in the plasma, so removing it works. Do not wait a week.
• Maintenance begins after the first attack, since NMOSD is relapsing in the great majority and disability accrues stepwise from attacks, not from steady progression. Vaccinate against meningococcus before starting a C5 inhibitor, and treat any fever on that drug as possible meningococcal sepsis.
• AQP4-negative? Send MOG-IgG. MOG antibody-associated disease favors bilateral simultaneous optic neuritis with disc edema and generally better visual recovery.